A thoracic tuberculous spondylodisctis after intravesical BCG immunotherapy of bladder cancer – Case report and literature review

Neurologia i Neurochirurgia Polska

Volumn 49, Issue 6, 2015, Pages 460-466

  Dąbrowska, Magda ^a   Drabarek, Tomasz ^a   Muraszko Klaudel, Anna ^a   Sławek, Jarosław ^a,b  

^a ST ADALBERT HOSPITAL   (Poland)

^b MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Bladder cancer; Spondylodiscitis; Tuberculosis

Indexed keywords

ANALGESIC AGENT; ANTIINFLAMMATORY AGENT; C REACTIVE PROTEIN; CEFTRIAXONE; ETHAMBUTOL; ISONIAZID; LINCOMYCIN; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN;

AGED; ARTICLE; BACKACHE; BLADDER CANCER; BOVINE TUBERCULOSIS; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER SURGERY; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; DEBRIDEMENT; DISEASE DURATION; DISKITIS; DRUG WITHDRAWAL; EPIDURAL ABSCESS; EYE EXAMINATION; HISTOPATHOLOGY; HOSPITAL ADMISSION; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPESTHESIA; LIMB WEAKNESS; LOW BACK PAIN; MALE; MEDICAL HISTORY; MYCOBACTERIUM BOVIS BCG; NEUROLOGIC DISEASE; NEUROPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOMYELITIS; PARAPLEGIA; PHYSICAL EXAMINATION; POSTOPERATIVE CARE; RADICULOGRAPHY; REHABILITATION CENTER; SCOLIOSIS; SPINAL CORD DECOMPRESSION; SPINE FRACTURE; THORACIC TUBERCULOUS SPONDYLODISCITIS; TRANSURETHRAL RESECTION; TUBERCULOUS SPONDYLITIS; VISUAL IMPAIRMENT; WEIGHT REDUCTION; ADVERSE EFFECTS; DISCITIS; IMMUNOTHERAPY; INTRAVESICAL DRUG ADMINISTRATION; MICROBIOLOGY; MYCOBACTERIUM BOVIS; PATHOGENICITY; PATHOLOGY; TUBERCULOSIS, SPINAL; URINARY BLADDER NEOPLASMS; VERTEBRA;

ADMINISTRATION, INTRAVESICAL; AGED; DISCITIS; HUMANS; IMMUNOTHERAPY; MALE; MYCOBACTERIUM BOVIS; THORACIC VERTEBRAE; TUBERCULOSIS, SPINAL; URINARY BLADDER NEOPLASMS;

EID: 84945953563     PISSN: 00283843     EISSN: 18974260     Source Type: Journal    
DOI: 10.1016/j.pjnns.2015.09.005     Document Type: Article

References (51)

1. [1] Chou, R., Qaseem, A., Snow, V., Casey, D., Cross, J.T. Jr., Shekelle, P., et al. Diagnosis and treatment of low back pain: a joint clinical practice guideline from the American College of Physicians and the American Pain Society. Clinical Guidelines. Ann Intern Med 147:7 (2007), 478–491.
2. [2] Manchikanti, L., Singh, V., Datta, S., Cohen, S.P., Hirsch, J.A., Comprehensive review of epidemiology, scope and impact of spinal pain. Pain Physician 12:July–August (4) (2009), E35–E70.
3. [3] Cottle, L., Riordan, T., Infectious spondylodiscitis. J Infect 56:June (6) (2008), 401–412.
4. [4] Trecarichi, E.M., Di Meco, E., Mazzotta, V., Fantoni, M., Tuberculous spondylodiscitis: epidemiology, clinical features, treatment, and outcome. Eur Rev Med Pharmacol Sci 16:April (Suppl. 2) (2012), 58–72.
5. [5] Gouliouris, T., Aliyu, S.H., Brown, N.M., Spondylodiscitis: update on diagnosis and management. J Antimicrob Chemother 65:November (Suppl. 3) (2010), iii11–iii24.
6. [6] Almeida, A., Tuberculosis of the spine and spinal cord. Eur J Radiol 55:August (2) (2005), 193–201.
7. [7] Böttiger, M., Romanus, V., de Verdier, C., Boman, G., Osteitis and other complications caused by generalized BCG-itis: experiences in Sweden. Acta Paediatr Scand 71 (1982), 471–478.
8. [8] Santbergen, B., Vriens, P.H., de Lange, W.C., Van Kasteren, M.E., Combined infection of vertebroplasty and aortic graft after intravesical BCG treatment. BMJ Case Rep, 2013, 2013.
9. [9] Abu-Nader, R., Terrell, C.L., Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical BCG use. Mayo Clin Proc 77:April (4) (2002), 393–397.
10. [10] Obaid, S., Weil, A.G., Rahme, R., Gendron, C., Shedid, D., Mycobacterium bovis spondylodiscitis after intravesical Bacillus Calmette-Guérin therapy. Surg Neurol Int, 2, 2011, 162.
11. [11] van Ingen, J., Rahim, Z., Mulder, A., Boeree, M.J., Simeone, R., Brosch, R., et al. Characterization of Mycobacterium orygis as M. tuberculosis Complex Subspecies. Emerg Infect Dis 18:April (4) (2012), 653–655.
12. [12] Nikaido, T., Ishibashi, K., Otani, K., Yabuki, S., Konno, S., Mori, S., et al. Mycobacterium bovis BCG vertebral osteomyelitis after intravesical BCG therapy, diagnosed by PCR-based genomic deletion analysis. J Clin Microbiol 45 (2007), 4085–4087.
13. [13] Morales, A., Eidinger, D., Bruce, A.W., Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors. J Urol 116:August (2) (1976), 180–183.
14. [14] Lamm, D.L., Efficacy and safety of Bacille Calmette-Guérin immunotherapy in superficial bladder cancer. Clin Infect Dis 31:September (Suppl. 3) (2000), S86–S90.
15. [15] Pérez-Jacoiste Asín, M.A., Fernández-Ruiz, M., López-Medrano, F., Lumbreras, C., Tejido, A., San Juan, R., et al. Bacillus Calmette-Guérin (BCG) infection following intravesical BCG administration as adjunctive therapy for bladder cancer: incidence, risk factors, and outcome in a single-institution series and review of the literature. Medicine (Baltimore) 93:October (17) (2014), 236–254.
16. [16] Prescott, S., Jackson, A.M., Hawkyard, S.J., Alexandroff, A.B., James, K., Mechanisms of action of intravesical bacille Calmette-Guérin: local immune mechanisms. Clin Infect Dis 31:September (Suppl. 3) (2000), S91–S93.
17. [17] Izzes, J.K., Thomas, C.B., Corticosteroid-associated fatal mycobacterial sepsis occurring 3 years after instillation of intravesical bacillus Calmette-Guerin. J Urol 150 (1993), 1498–1500.
18. [18] Vazquez-Lavista, L.G., Flores-Balcazar, C.H., Llorente, L., The bacillus Calmette-Guerin as immunomodulator in bladder cancer. Rev Invest Clin 59 (2007), 146–152.
19. [19] Bohle, A., Brandau, S., Immune mechanisms in bacillus Calmette-Guerin immunotherapy for superficial bladder cancer. J Urol 170 (2003), 964–969.
20. [20] Newman, J.R., Clough, L.A., Merino, F., Mycobacterium bovis osteomyelitis of the thoracic spine mimicking a metastatic lytic lesion in a patient exposed to intravesicular bacille Calmette-Guérin treatment. Urol Case Rep 2 (2014), 142–144.
21. [21] Katz, D.S.H., Wogalter, H., D'Esposito, R.F., Cunha, B.A., Mycobacterium bovis vertebral osteomyelitis and psoas abscess after intravesical BCG therapy for bladder carcinoma. Urology 40 (1992), 63–66.
22. [22] Aljada, I.S., Crane, J.K., Corriere, N., Wagle, D.G., Amsterdam, D., Mycobacterium bovis BCG causing vertebral osteomyelitis (Pott's disease) following intravesical BCG therapy. J Clin Microbiol 37 (1999), 2106–2108.
23. [23] Morgan, M.B., Iseman, M.D., Mycobacterium bovis vertebral osteomyelitis as a complication of intravesical administration of Bacille Calmette-Guerin. Am J Med 100 (1996), 372–373.
24. [24] Samadian, S., Phillips, F.M., Deeab, D., Mycobacterium bovis vertebral osteomyelitis and discitis with adjacent mycotic abdominal aortic aneurysm caused by intravesical BCG therapy: a case report in an elderly gentleman. Age Ageing 42 (2013), 129–131.
25. [25] Colebatch, A.N., Mounce, K.E., Mycobacterium bovis discitis as a complication of intravesical Bacillus Calmette-Guerin therapy. J Clin Rheumatol 16 (2010), 74–75.
26. [26] Civen, R., Berlin, G., Panosian, C., Vertebral osteomyelitis after intravesical administration of bacille Calmette-Guerin. Clin Infect Dis 18 (1994), 1013–1014.
27. [27] Fishman, J.R., Walton, D.T., Flynn, N.M., Benson, D.R., deVere White, R.W., Tuberculous spondylitis as a complication of intravesical bacillus Calmette-Guerin therapy. J Urol(149), 1993, 584–587.
28. [28] Patel, A.R., Sabanegh, E.S., Jones, J.S., Gordon, S.M., Ballin, M., Ruggieri, P.M., et al. Bacillus Calmette-Guerin osteomyelitis mimicking spinal metastasis from urothelial cell carcinoma of the bladder. Eur Urol 58 (2010), 934–937.
29. [29] Mavrogenis, A.F., Sakellariou, V.I., Tsiodras, S., Papagelopoulos, P.J., Late Mycobacterium bovis spondylitis after intravesical BCG therapy. Joint Bone Spine 76 (2009), 296–300.
30. [30] Rozenblit, A., Wasserman, E., Marin, M.L., Veith, F.J., Cynamon, J., Rozenblit, G., Infected aortic aneurysm and vertebral osteomyelitis after intravesical bacillus Calmette-Guerin therapy. AJR Am J Roentgenol 167 (1996), 711–713.
31. [31] Dahl, T., Lange, C., Odegard, A., Bergh, K., Osen, S.S., Myhre, H.O., Ruptured abdominal aortic aneurysm secondary to tuberculous spondylitis. Int Angiol 24 (2005), 98–101.
32. [32] Sugita, Y., Chokyu, H., Gotoh, A., Maeda, H., Umezu, K., Nakano, Y., Tuberculous spondylitis after intravesical BCG instillation: a case report. Nihon Hansen Gakkai Zasshi 86 (1995), 1493–1496.
33. [33] Josephson, C.B., Al-Azri, S., Smyth, D.J., Haase, D., Johnston, B.L., A case of Pott's disease with epidural abscess and probable cerebral tuberculoma following Bacillus Calmette-Guérin therapy for superficial bladder cancer. Can J Infect Dis Med Microbiol 21:1 (2010), e75–e78.
34. [34] Seelig, M.H., Oldenburg, W.A., Klingler, P.J., Blute, M.L., Pairolero, P.C., Mycotic vascular infections of large arteries with Mycobacterium bovis after intravesical bacillus Calmette-Guérin therapy: case report. J Vasc Surg 29 (1999), 377–381.
35. [35] Bowyer, L., Hall, R.R., Reading, J., Marsh, M.M., The persistence of bacilli Calmette-Guerin in the bladder after intravesical treatment for bladder cancer. Br J Urol 752 (1995), 188–192.
36. [36] Altare, F., Durandy, A., Lammas, D., Emile, J.F., Lamhamedi, S., Le Deist, F., et al. Impairment of mycobacterial immunity in human interleukin-12 receptor deficiency. Science 280:5368 (1998), 1432–1435.
37. [37] Ferrer, M.F., Torres, L.G., Ramírez, O.A., Rumayor Zarzuelo, M., del Prado González, N., Tuberculosis of the spine. A systematic review of case series. Int Orthop 36:February (2) (2012), 221–231.
38. [38] Weng, C.Y., Chi, C.Y., Shih, P.J., Ho, C.M., Lin, P.C., Chou, C.H., et al. Spinal tuberculosis in non-HIV-infected patients: 10 year experience of a medical center in central Taiwan. J Microbiol Immunol Infect 43 (2010), 464–469.
39. [39] Jain, A.K., Tuberculosis of the spine: a fresh look at an old disease. J Bone Joint Surg Br 92:July (7) (2010), 905–913.
40. [40] Garg, R.K., Somvanshi, D.S., Spinal tuberculosis: a review. J Spinal Cord Med 34:5 (2011), 440–454.
41. [41] Maeda, Y., Izawa, K., Nabeshima, T., Yonenobu, K., Tuberculous spondylitis in elderly Japanese patients. J Orthop Sci 13 (2008), 16–20.
42. [42] Colmenero, J.D., Jiménez-Mejías, M.E., Reguera, J.M., Palomino-Nicás, J., Ruiz-Mesa, J.D., Márquez-Rivas, J., et al. Tuberculous vertebral osteomyelitis in the new millennium: still a diagnostic and therapeutic challenge. Eur J Clin Microbiol Infect Dis 23 (2004), 477–483.
43. [43] Turgut, M., Spinal tuberculosis (Pott's disease): its clinical presentation, surgical management, and outcome. A survey study on 694 patients. Neurosurg Rev 24 (2001), 8–13.
44. [44] Rasouli, M.R., Mirkoohi, M., Vaccaro, A.R., Yarandi, K.K., Rahimi-Movaghar, V., Spinal tuberculosis: diagnosis and management. Asian Spine J 6:4 (2012), 294–308.
45. [45] Lange, C., Abubakar, I., Alffenaar, J-WC., Bothamley, G., Caminero, J.A., Carvalho, A.C., et al. Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement. Eur Respir J 44:1 (2014), 23–63.
46. [46] Rischmann, P., Desgrandchamps, F., Malavaud, B., Chopin, D.K., BCG intravesical instillations: recommendations for side-effects management. Eur Urol 37:Suppl. 1 (2000), 33–36.
47. [47] World Health Organization, WHO Report 2003. Treatment of tuberculosis: Guidelines for national programmes., 2003, World Health Organization, Geneva.
48. [48] Clavel, G., Grados, F., Lefauveau, P., Fardellone, P., Osteoarticular side effects of BCG therapy. Int Bone Spine 73:January (1) (2006), 24–28.
49. [49] Kahana, L.M., Toxic ocular effects of ethambutol. CMAJ 137:3 (1987), 213–216.
50. [50] Chan, R.Y., Kwok, A.K., Ocular toxicity of ethambutol. Hong Kong Med J 12:February (1) (2006), 56–60.
51. [51] Babashahi, A., Mortazaviha, S., Zaim, I., Ranjbar, F., Safari, H., Teymoori, A., et al. Upper thoracic spine tuberculosis with pathologic fracture and cord compression. Internet J Spine Surg, 6(2), 2012.